R1 RCM Inc

R1 RCM — Merger or Acquisition (February 2018)

28 slides from R1 RCM's merger presentation, Feb 26, 2018

  1. Slide 1: R1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business

    R1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business Investor Presentation February 26, 2018

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures

    2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not

  3. Slide 3: The One Revenue Cycle Partner for Providers

    3 THE ONE REVENUE CYCLE PARTNER FOR PROVIDERS. Across evolving payment models, partner engagement structures, and settings of care. OUR VISION IS TO BE…

  4. Slide 4: Advancing our Vision to be the One Revenue Cycle Partner for Providers

    4 Enterprise Value Relaunch Effective re-launch of company Solidify Acute Care Lead Strengthen acute care position via Ascension deployment Extend Integrated Solution Further build out integrated revenue cycle (acute care + physician) across payment models Phase 3 Phase 2 Phase 1 Advancing our Visio

  5. Slide 5: What We Are Announcing Today

    5 What We Are Announcing Today Signing of Definitive Agreement to Purchase Intermedix 1 2 Term Sheet to be RCM Services Provider for Ascension Medical Group

  6. Slide 6: Agenda

    6 Agenda Transaction Rationale Intermedix Overview Strategic Rationale Financial Outlook 1 2 3 4

  7. Slide 7: Intermedix Transaction Overview

    7 Intermedix Transaction Overview Transaction Terms ▪ Transaction valued at approximately $460M (cash) ▪ Implied multiple of ~7.9x LTM 9/30/17 adjusted EBITDA1 (includes only cost synergies) ▪ Subject to signing of Ascension Medical Group contract, HSR approval and other customary closing conditions

  8. Slide 8: Transaction Rationale

    8 Transaction Rationale Accelerates Growth Trajectory ▪ Enables expansion into Ascension Medical Group ▪ Drives onboarding of physician NPR ▪ Expands target addressable market (TAM) from $60B to $100B1 Improves Revenue Mix ▪ Diversifies revenue mix − Increases non-Ascension revenue − Increases non-A

  9. Slide 9: Agenda

    9 Agenda Transaction Rationale Intermedix Overview Strategic Rationale Financial Outlook 1 2 3 4

  10. Slide 10: Intermedix at a Glance

    10 Scaled Platform Differentiated Capabilities Intermedix at a Glance ▪ Experience across settings of care ▪ End-to-End Physician RCM offering ▪ Full suite of practice management services with technology ▪ Significant investment in data analytics and automation ▪ Clinical insights platform well-posi

  11. Slide 11: Intermedix Financial Profile

    11 Intermedix Financial Profile $193MLTM September 2017 Revenue $48MLTM September 2017 Adj. EBITDA ~$4.2BAnnual Net Patient Revenue DiversifiedRevenue Profile

  12. Slide 12: Agenda

    12 Agenda Transaction Rationale Intermedix Overview Strategic Rationale Financial Outlook 1 2 3 4

  13. Slide 13: Intermedix Acquisition Extends R1's End-To-End RCM Platform

    13 Intermedix Acquisition Extends R1’s End-To-End RCM Platform Strategic Fit Addresses Key Healthcare Challenges ▪ Intermedix adds deep capabilities to serve non-acute care settings at scale ▪ Buildout of integrated RCM platform addresses workflow challenges across care settings ▪ Visibility across

  14. Slide 14: Addresses Key Healthcare Challenges

    14 Addresses Key Healthcare Challenges 1 Strategic Fit Challenges Faced by Providers Our Solutions ▪ Scheduling and order management across care settings ▪ Single point of contact for administrative/billing questions Patient and Physician Satisfaction ▪ Drive scale/reduce duplicative cost between ca

  15. Slide 15: Intermedix Adds Capabilities Across the Continuum of Care

    15 1 Intermedix Adds Meaningful Capabilities to Serve Customers Across the Continuum of Care Strategic Fit End Market Acute Care Hospital-Based Physicians Office-Based Physicians Alternate Site Emergency Medical Services IMX IMX+

  16. Slide 16: Accelerates Onboarding of Significant Physician NPR

    16 Accelerates Onboarding of Significant Physician NPR 2 Accelerates Growth Note1: Ascension Medical Group (AMG) contract expected to be signed in connection with close of Intermedix transaction; $0.5B of AMG opportunity signed May 2017. Note2: Presence Health contract expected to be signed in the s

  17. Slide 17: Targeting Large, Growing Industry; Expands TAM

    17 Targeting Large, Growing Industry. R1 Expects to Grow 2x Faster. 2 Expands our TAM 12% Projected CAGR through 2020 25%+ Projected CAGR through 2020 Target Industry Expands TAM to $100B1 External RCM Spend Growing Steadily2… …R1 Revenue Expected to Grow Faster $60 $100 $B $40 Historical Served New

  18. Slide 18: IMX Acquisition Adds Critical MSO Services to R1 Product Portfolio

    18 IMX Acquisition Adds Critical MSO Services to R1 Product Portfolio 2 Accelerates Growth ▪ Optimizes physician financial performance and increases market reach ▪ Expands suite of services & opens new channel for growth ▪ Fits with flexible engagement model and operating infrastructure ▪ Enables al

  19. Slide 19: Accelerates Buildout of Physician Platform

    19 Accelerates Buildout of Physician Platform Advances our Solution Capabilities Provider Recruitment, Enrollment & Credentialing Payor Benchmarking & Negotiation Administrative Services, Performance Mgmt. Orders, Outreach & Scheduling Pre-Registration / Financial Clearance Financial Counseling Chec

  20. Slide 20: Advances our Technology Solutions

    20 Advances our Technology Solutions Advances our Solution Capabilities ▪ Strengthens Descriptive, Performance, & Predictive Analytics ▪ Extends lead in RCM Workflow Technology & expands Robotic Process Automation (RPA) Suite ▪ Improves Charge Capture, Coding, Billing & Contract Modeling solutions ▪

  21. Slide 21: Agenda

    21 Agenda Transaction Rationale Intermedix Overview Strategic Rationale Financial Outlook 1 2 3 4

  22. Slide 22: Overview of Financing

    22 Overview of Financing ▪ Committed financing in place as follows: − New $270M first lien term loan − New $110M subordinated debt facility from Ascension/TowerBrook ▪ Remainder to be financed from cash on hand ▪ < 2.5x net leverage expected Q4 2018 < 2.5x < 0.5x Q4 2018 Q4 2020 Expected Net Debt/Ad

  23. Slide 23: Preliminary 2018 Financial Outlook

    23 Preliminary 2018 Financial Outlook1 $M Prior 2018 Outlook Revenue 675 – 725 GAAP Operating Income 5 – 15 Adjusted EBITDA 40 – 50 NPR growth assumptions – $B New customer 3.0 Total $3.0 Updated 2018 Outlook 850 – 900 ($30)-($55) 50 – 55 NPR growth assumptions – $B Intermountain Health 4.6 Presence

  24. Slide 24: Preliminary 2020 Financial Outlook

    24 Preliminary 2020 Financial Outlook1 $M Prior 2020 Outlook Revenue 800 – 900 GAAP Operating Income 80 – 100 Adjusted EBITDA 120 – 135 Updated 2020 Outlook 1,200 – 1,300 115 – 155 225 – 250 Note: Adjusted EBITDA is a non-GAAP measure, please refer to the Appendix for a reconciliation of non-GAAP fi

  25. Slide 25: R1 + Intermedix Strategically and Financially Compelling Transaction

    25 R1 + Intermedix Strategically and Financially Compelling Transaction Delivers Critical Capabilities at Scale to Support R1’s Growth Strategy ▪ Enables R1 to accelerate onboarding of $3.2B physician NPR ▪ Complementary areas of expertise create comprehensive offering across the care continuum ▪ En

  26. Slide 26: Appendix

    Appendix

  27. Slide 27: Use of Non-GAAP Financial Measures

    27 Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, wh

  28. Slide 28: Reconciliation of GAAP to Non-GAAP Financials

    28 Reconciliation of GAAP to Non-GAAP Financials $ in millions Prior Outlook (provided on 1/08/18)Updated 2018 and 2020 Outlook $ in millions $ in millions Reconciliation of Intermedix GAAP to non-GAAP

R1 RCM — Merger or Acquisition (February 2018) on 6ix